Huayu Pharmaceutical announced the merger with Jianru Pharma to accelerate the energy of pharmaceutical research and development
2018/5/8 Finishing/Editorial Department
Published on 2018-05-08 Author: Reporter Xu Jing — No response ↓
Uni Pharma Co., Ltd. (abbreviation: Huayu Pharmaceutical, code: 6621) held a press conference at the Securities Counter Trading Center today (8th) to formally explain and announce that the board of directors of the two companies held a meeting today and resolved to approve the merger with Jianru Pharmaceutical Co., Ltd. (abbreviation: Jianru).
Huayu Pharmaceutical said in public information that in the past, the core of its operation was mainly medical services and product agency marketing close to the clinical end, and this time, with the R&D expertise of Jianru Pharmaceutical, Huayu Pharmaceutical will transform from an agent marketing professional to an internationally competitive R&D pharmaceutical company.
The outstanding results of ADEPT anti-stick solution marketed by Huayu Pharmaceutical are confirmed by the original Baxter Healthcare. ADEPT Anti-Sticking Solution provides all-round protection during abdominal surgery and reduces the effect of sticking, and is widely trusted and widely used by clinicians.
In addition, Huayu Pharmaceutical has a deep understanding of the advantages and future development of minimally invasive surgery in the diagnosis and treatment of cancer with tumor marker DR-70 enzyme immunoassay diagnostic reagent (DR-70) and radiofrequency ablation technology (RFA), so it is expected to develop RFA 2.0 to enter the world in the future in cooperation with ITRI on RFA’s minimally invasive liver cancer related needles and the guidance system of Haoyu Biomedical Co., Ltd.
Kinru is a specialty drug R&D company specializing in the development of innovative dosage forms, searching for new products (505(b)2 new drugs) with patient needs and market competitiveness, including generic drugs with high technology or patent barriers, high barriers to entry, and the application of patented oral solid release control agent technology platform.
Therefore, if the two parties merge, Huayu Pharmaceutical’s marketing expertise and Jianru’s R&D capabilities will complement each other, which can not only push forward the existing cooperative projects more effectively, but also quickly find the most internationally competitive products and establish an innovative and marketable product pipeline under the “one-stop” operation.
Under this structure, Huayu Pharmaceutical is the surviving company, and Jianru is the elimination company; The name of the surviving company after the merger is Uni Pharma Co., Ltd.. The tentative share exchange ratio between Jianru and Huayu Pharmaceutical is 1:1 (i.e., 1 ordinary share of Huayu Pharmaceutical for every 1 ordinary share of Jianru), and after the merger, the paid-in capital of Huayu Pharmaceutical will be approximately 354 million yuan. The proposal will be discussed and approved at the general meeting of shareholders of the two companies on June 19 this year and approved by the competent authority, and the merger base date is tentatively set as September 1 this year. http://www.gbimonthly.com/2018/05/23789/
